George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
https://www.veronapharma.com/media/verona-pharma-announces-ensifentrine-meets-primary-endpoint
https://www.veronapharma.com/media/verona-pharma-reports-second-quarter-2022-financial-results-and
Seems to be reporting trial results much earlier than expected. Hopefully a good sign....
It's SHOWTIME!!!!
Shame Rhodi et al decided to bail when they did, looks like this might pay off for the lth...best of luck to us all...
Top line data presenting tomorrow! Good After market SP action.
Last top up today, just have to wait and see how things play out between now and end of year.
Can't see any reason why SP is as low as current level, but good top up price.
Shhhhhh but we seem to be building momentum towards the results of P3 Enhance 2, due this qtr.
Expect it'll be late August/early September when Enhance 2 results published given when enrolment completed and trial is 24 weeks.
I note that enrolment for Enhance P3 trials is complete. Enhance 2 data expected Q3 and Enhance 1 at year end. GL all LT holders.
I have bought a few VRNA to average down due to continued belief. I am also very happy that the P3 end point targets are based on FEV and general improvement in well being. FEV has always been good in every previous trial, so I personally believe that the prospects for success are good, and on that basis, I look forward to results
Thanks Digger.
Thanks a lot. I held quite a few for 10 years and when the price went low I added to it but it's never really bounced back. I jut hope i'm proved right eventually.
If you continued to hold in the hope of getting your money back you might just about do it...but if you are expecting a profit really had to top up when the SP hit the lows...
Just looks to me like a good time to get your average down as phase three results due over next 6 months and it looks like this is an attempt by the company to raise the profile ahead of results:
https://www.veronapharma.com/media/verona-pharma-host-kol-event-june-16-2022
Thanks Digger. So we're saying that the price is still less than 2p old money which is shocking. I do think that the Market Makers are manipulating this share as on Friday, people had bought 1000s and when someone sold a small amount of shares relative to purchases it plunged by 10%. Lets hope the estimate by the professional s of between £25-30 a share comes true this year.
Current SP $4.76 @ £1 = $1.25 = £3.81
8 shares per ADS @ £3.81/8 = £0.476
Then /50 so in “old Aim money” 0.95p
Do still under a penny. I agree that this investment has been a long painful journey, but this year for phase 3 results??
Thanks Digger and Barbershop. Barbershop just to clarify, as Digger mentioned the company felt that that it needed to stop being a penny share so we were given 1 share for every 8 we held. When Verona was listed on the Nasdaq it was 1 new share for 50 of the old shares which as I mentioned in my previous post currently puts the current old penny price (if that makes sense) at 1.25p which is shocking. I remember this share going up to 16p when it was a penny share which at todays rate would make it £60 per share. How the mighty have fallen. My loyalty to this bl**dy share has been so misplaced having been in it for 12 years now, I would have had more success buying a hog roast cart and setting it up outside a vegetarians convention. At least I'd still have the cart and the the pork.
You are correct!
50:1 was a dilution at some point before US listing.
I have held since 2009. I continued to add and need about $20 to break even. Not my best investment!
When we dual listed on Nasdaq, each VRNA (ADS) share was comprised of 8 VRP shares...so you're right that if you held 8 AIM listed VRP shares you would get 1 VRNA share if you elected to continue holding.
Not sure where you're getting the 50:1 from as it was always 8:1
Can someone refresh my memory. I' m trying to equate back what the current share price in pence would be for verona pharma at the current approx price of £5. Am I right in thinking the american share was 1 share per 50 old shares which would make the current price 10p per share and then am I right in thinking that in the uk we got 1 new share per 8 old penny shares which would make the current price per share 1.25p per share which if true is ridiculous but maybe someone like Rhodi with a better memory than mine can correct me.. Many thanks
Managed to top up with HL as Halifax don't seem to allow it.
Seems a great opportunity at these levels with Phase 3 results due by end of Q3 and again by end of Q4.
Many an investor lowered their holding when the directors missed that opportunity. Like you say just one of a catalog of strewn errors. But hey if I can keep accumulating free shares then happy as Larry. There was a very knowledgeable poster on ADVFN that relinquished shares and was totally mystified at the missed "opportunity" as you quite correctly state.
Well that’s no surprise that we have to pay substantial royalties. They had a good opportunity to buy this company but missed the opportunity.
Another poor decision.
If you can't see the posts then how can you judge their relevance? Absolute Muppet....
Wow it is a stalker from another board as I have no one barred from this board. How sad and no doubt upset by my factual post. Why do they bother when their posts are so irrelevant. Probably off on a tangent spouting *******s as usual.
Not sure what that rants all about, think the recent dip in SP might have something to do with events in Ukraine.
If that's inconvenienced you in some small way just be glad you don't live somewhere that's under constant bombardment by the Russians
But as I have free carry I do not mind. Sadly they have missed every time schedule they have ever set. What ever happened to us trialing enisfenterine to help cystic fibrosis. Well happily a new drug is being very successfully used by sufferers and is proving amazing, needless to say has nothing to do with VRNA. IMO they have a knack of missing the boat or making poor decisions. Hopefully it will change one day. Looking at the report they still seem to go through money on the administration line like it is water. Not surprised to see the sell off again. Back to $4.50 and below no doubt and then rinse repeat. Digger and Izstar and all other investors keep well. Fingers crossed one day this will be more than what many an investor would describe as a lifestyle company. 2023 for any proper value enhancing sp news imo.